Incyte Biosciences International
GPTKB entity
Statements (24)
| Predicate | Object |
|---|---|
| gptkbp:instance_of |
gptkb:biotechnology
|
| gptkbp:acquisition |
gptkb:Incyte_Corporation
|
| gptkbp:ceo |
gptkb:Herbert_H._Schwartz
|
| gptkbp:clinical_trial |
ongoing
|
| gptkbp:employees |
over 1,000
|
| gptkbp:focus |
gptkb:cancer_treatment
|
| gptkbp:founded |
gptkb:1991
|
| gptkbp:founder |
gptkb:Paul_Friedman
|
| gptkbp:headquarters |
gptkb:Wilmington,_Delaware
|
| https://www.w3.org/2000/01/rdf-schema#label |
Incyte Biosciences International
|
| gptkbp:industry |
gptkb:pharmaceuticals
|
| gptkbp:partnerships |
gptkb:Medi_Wound
gptkb:Bristol-Myers_Squibb gptkb:Novartis |
| gptkbp:products |
gptkb:Iclusig
gptkb:Jakafi gptkb:Pemigatinib |
| gptkbp:research_areas |
oncology
autoimmune diseases hematology |
| gptkbp:traded_on |
gptkb:NASDAQ
|
| gptkbp:website |
www.incyte.com
|
| gptkbp:bfsParent |
gptkb:Incyte_Biosciences
|
| gptkbp:bfsLayer |
6
|